1-烯丙氧基-4-氯-2-甲基-苯 | 68536-94-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-烯丙氧基-4-氯-2-甲基-苯
• 英文名称: Benzene, 4-chloro-2-methyl-1-(2-propenyloxy)-
• 英文别名: 4-chloro-2-methyl-1-prop-2-enoxybenzene
• CAS: 68536-94-7
• 化学式: C₁₀H₁₁ClO
• mdl: MFCD27998467
• 分子量: 182.65
• InChiKey: AAQOQZIXBMOVRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-烯丙氧基-4-氯-2-甲基-苯 在 氯化亚砜 、 jones' reagent 、 Kieselgel 60 、 氨 、 sodium methylate 、 phosphorus pentoxide 、 间氯过氧苯甲酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 丙酮 、 甲苯 、 苯 为溶剂， 反应 104.92h， 生成 2-(5-Chloro-7-methyl-2,3-dihydro-benzofuran-2-yl)-4,5-dihydro-1H-imidazole
  参考文献：
  名称：

  .alpha.-Adrenoceptor reagents. 2. Effects of modification of the 1,4-benzodioxan ring system on .alpha.-adrenoreceptor activity

  摘要：

  Modification of the 1,4-benzodioxan ring present in RX 781094 has not previously been considered. This paper describes a number of analogues of this ring system, including compounds in which one of the oxygen atoms has been replaced by a methylene group and also those in which the ring size has been changed to give, for example, furan and thiophene derivatives. The dihydrobenzofuranylimidazoline compound 7 is the only analogue possessing presynaptic antagonist potency potency and selectivity comparable to that of 1. In view of this result, a number of derivatives was prepared to determine the structure-activity relationships within this series. Many derivatives, as well as the parent compound 7, were found to possess presynaptic alpha 2-adrenoreceptor antagonist and postsynaptic alpha 1-adrenoreceptor partial agonist properties. Two of the selective presynaptic antagonists, 13 and 14 possess greater potency and selectivity than that possessed by 1. The 5-chloro derivative 25 is twice as potent as after oral administration but only about half as potent when given intravenously.

  DOI：

  10.1021/jm00371a003
• 作为产物：
  描述：

  4-Chloro-2-methyl-1-[((Z)-propenyl)oxy]-benzene 在 potassium tert-butylate 作用下， 以 二甲基亚砜 为溶剂， 生成 1-烯丙氧基-4-氯-2-甲基-苯
  参考文献：
  名称：

  Thermodynamic, spectroscopic, and density functional theory studies of allyl aryl and prop-1-enyl aryl ethers. Part 1. Thermodynamic data of isomerization

  摘要：

  通过对70对异构化的烯丙基苯基醚（a）和（Z）-丙-1-烯基苯基醚（b）在DMSO溶液中的化学平衡研究，考察了它们相对热力学稳定性的变化。从平衡常数随温度的变化中，评估了在298.15 K下的异构化吉布斯自由能、焓和熵。由于其低焓值，（Z）-丙-1-烯基苯基醚在平衡状态下具有显著优势，a→b异构化的吉布斯自由能范围从-12至-23 kJ/mol。在大多数反应中，熵的贡献可以忽略不计，但偶尔会发现小于+10 J/K·mol的正值。平衡研究还扩展到涉及两对在烯键C(2)位置带有甲基取代基的相关异构化醚。甲基取代基可以增加烯丙基醚的相对热力学稳定性约3.4 kJ/mol。

  DOI：

  10.1039/b101837j

文献信息

• Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids
  作者：H. Jendralla、E. Granzer、B. Von Kerekjarto、R. Krause、U. Schacht、E. Baader、W. Bartmann、G. Beck、A. Bergmann

  DOI：10.1021/jm00114a004

  日期：1991.10

  HMG-CoA reductase inhibitors, after po administration to rats decreased serum lipoproteins and increased HDL/LDL ratio better than probucol (Table VII). HMG-CoA reductase inhibitor 11ll and phenolic building blocks 8, notably 8jj and 8kk, inhibited LDL oxidation in vitro (Table VIII). Chemical structure-activity relationships (Table IX) and the pharmacological profile of phenoxy-type inhibitors 11 diverged

  这些化合物中的每一种在口服给予狗后仅具有中等活性（表VI）。向大鼠口服给药后，化合物di-11ii（一种普罗布考和HMG-CoA还原酶抑制剂的结构元素的混合物）比普罗布考更好地降低了血清脂蛋白并提高了HDL / LDL比（表VII）。HMG-CoA还原酶抑制剂11ll和酚结构单元8，特别是8jj和8kk，在体外抑制LDL氧化（表VIII）。苯氧基型抑制剂11的化学结构-活性关系（表IX）和药理特性与已知的HMG-CoA还原酶抑制剂不同。HMG-CoA还原酶抑制剂11ll和酚结构单元8，特别是8jj和8kk，在体外抑制LDL氧化（表VIII）。苯氧基型抑制剂11的化学结构-活性关系（表IX）和药理特性与已知的HMG-CoA还原酶抑制剂不同。HMG-CoA还原酶抑制剂11ll和酚结构单元8，特别是8jj和8kk，在体外抑制LDL氧化（表VIII）。苯氧基型抑制剂11的化学结构-活性关系（表IX
• MANUFACTURING PROCESS FOR NO-DONATING COMPOUNDS SUCH AS NO-DONATING DICLOFENAC
  申请人：ANDERSSON Johan

  公开号：US20090170934A1

  公开（公告）日：2009-07-02

  The present invention relates to a new process for the preparation of NO-donating compounds using a sulfonated intermediate. The invention relates to new intermediates prepared therein suitable for large scale manufacturing of NO-donating compounds. The invention further relates to the use of the new intermediates for the manufacturing of pharmaceutically active NO-donating compounds. The invention further relates to a substantially crystalline form of NO-donating NSAIDs, especially 2-[2-(nitrooxy)ethoxy]ethyl 2-[(2,6-dichlorophenyl)amino]phenyl}acetate, the preparation thereof and to pharmaceutical formulations containing said crystalline form and to the use of said crystalline form in the preparation of a medicament.

  本发明涉及一种使用磺化中间体制备NO供体化合物的新工艺。该发明涉及其中制备的适用于NO供体化合物大规模生产的新中间体。本发明还涉及使用新中间体制造药用活性NO供体化合物。此外，本发明还涉及NO供体NSAIDs的实质晶体形式，特别是2-[2-(硝氧基)乙氧基]乙基2-[(2,6-二氯苯基)氨基]苯基}乙酸酯的制备，以及含有该晶体形式的制药配方和在制备药物时使用该晶体形式的用途。
• Addition of Nitrile Oxides to Aryl Allyl Ethers
  作者：E. Alksnis、V. Muravenko、V. Dirnens、E. Lukevics

  DOI：10.1023/b:cohc.0000040778.88220.e3

  日期：2004.6